Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation

This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation.The study consists of two stages I, Stage I ：explores the combination dose and the second phase; Stage II ：patients were randomized 1:1 to receive either the experimental regimen DN022150 plus AG or the control regimen AG alone.

NCT Number	NCT07656376
Lead Sponsor	Jiangxi Kvvit Pharmaceutical Co., Ltd.
Conditions	Pancreatic Cancer, Pancreatic Carcinoma
Enrollment	465 participants
Start Date	2027-06-06
Primary Completion	2029-02-07 (estimated)
Study Completion	2029-05-08 (estimated)
Updated on ClinicalTrials.gov	2026-06-18